第31届急性疾病质量倡议共识会议关于急性肾损伤临床试验设计的推荐:共识声明
针对急性肾损伤(AKI)缺乏新型预防或治疗干预的现状,第31届急性疾病质量倡议(ADQI)会议召集重症、肾脏病(含成人与儿科)、生物统计学专家及有亲身经历者(PWLE),聚焦四个领域:患者富集策略、预防与减轻研究、治疗研究、非传统随机对照试验的创新设计。采用改良Delphi流程,基于现有数据形成推荐与共识声明,最终采纳需专家组成员>90%同意。专家组共制定12条共识声明,涉及临床试验终点、适当时应用富集策略以及纳入PWLE参与试验设计,并考虑了创新试验设计。作者结论认为,当前AKI预防或治疗缺乏特异性疗法,需要完善未来临床试验设计,本共识报告试图解决这些问题,包括使用预测性和预后性富集策略以实现合适的患者选择。
要点
- 第31届ADQI共识会议采用改良Delphi流程,最终采纳共识声明需专家组成员>90%同意。
- 专家组共制定12条共识声明,涵盖临床试验终点、适当时应用富集策略以及纳入有亲身经历者(PWLE)参与试验设计。
- 共识聚焦四个领域:患者富集策略、预防与减轻研究、治疗研究、非传统随机对照试验的创新设计。
- 作者结论指出当前AKI预防或治疗缺乏特异性疗法,需完善未来临床试验设计。
- 共识报告试图解决包括使用预测性和预后性富集策略以实现合适患者选择在内的试验设计问题。
适用人群与场景
- 急性肾损伤(AKI)预防或治疗临床试验的研究者与设计者
- 涉及成人及儿科的危重症与肾脏病领域
研究设计与关键结果
- 第31届急性疾病质量倡议(ADQI)会议召集重症、肾脏病(含成人与儿科)、生物统计学专家及有亲身经历者(PWLE),聚焦四个领域:患者富集策略、预防与减轻研究、治疗研究、非传统(平行臂或整群)随机对照试验之外的创新试验设计。
- 采用改良Delphi流程,基于现有数据形成推荐与共识声明,最终采纳需专家组成员>90%同意。
- 专家组共制定12条共识声明,涉及临床试验终点、适当时应用富集策略以及纳入PWLE参与试验设计,并考虑了创新试验设计。
证据类型、等级与局限
- 证据类型:共识声明(第31届ADQI会议),采用改良Delphi流程,最终采纳需专家组成员>90%同意。
- 局限:原文未报告局限性
对床旁实践的改变
- 作者认为,当前AKI预防或治疗缺乏特异性疗法,需要完善未来临床试验设计,包括使用预测性和预后性富集策略以实现合适的患者选择。
- 共识声明提出在临床试验中纳入有亲身经历者(PWLE)参与试验设计。
指南或共识出处
- 第31届急性疾病质量倡议(ADQI)共识会议共识声明,发表于Intensive Care Med
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
PURPOSE: Novel interventions for the prevention or treatment of acute kidney injury (AKI) are currently lacking. To facilitate the evaluation and adoption of new treatments, the use of the most appropriate design and endpoints for clinical trials in AKI is critical and yet there is little consensus regarding these issues. We aimed to develop recommendations on endpoints and trial design for studies of AKI prevention and treatment interventions based on existing data and expert consensus.
METHODS: At the 31st Acute Disease Quality Initiative (ADQI) meeting, international experts in critical care, nephrology, involving adults and pediatrics, biostatistics and people with lived experience (PWLE) were assembled. We focused on four main areas: (1) patient enrichment strategies, (2) prevention and attenuation studies, (3) treatment studies, and (4) innovative trial designs of studies other than traditional (parallel arm or cluster) randomized controlled trials. Using a modified Delphi process, recommendations and consensus statements were developed based on existing data, with > 90% agreement among panel members required for final adoption.
RESULTS: The panel developed 12 consensus statements for clinical trial endpoints, application of enrichment strategies where appropriate, and inclusion of PWLE to inform trial designs. Innovative trial designs were also considered.
CONCLUSION: The current lack of specific therapy for prevention or treatment of AKI demands refinement of future clinical trial design. Here we report the consensus findings of the 31st ADQI group meeting which has attempted to address these issues including the use of predictive and prognostic enrichment strategies to enable appropriate patient selection.
参考来源
- Zarbock A, Forni LG, Koyner JL, et al. Recommendations for clinical trial design in acute kidney injury from the 31st acute disease quality initiative consensus conference. A consensus statement. Intensive Care Med. 2024. PMID: 39115567. doi:10.1007/s00134-024-07560-y
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。